title: Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
abstract: We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD. The 3-year OS, PFS, relapse rates and 1-year non-relapse mortality (NRM) were 63%, 59%, 21% and 20%, respectively. Uncontrolled disease status and high hematopoietic cell transplantation comorbidity index (HCT-CI) were associated with lower OS, whereas PBSC was an independent protective factor. Uncontrolled disease and HCT-CI >2 was predictive for NRM. Finally, disease status other than CR was predictive of relapse. In conclusion, haplo-HSCT is a valid treatment in advanced HL, offering excellent rates of survival and acceptable toxicities.
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Castagna
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bramanti
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Devillier
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Sarina
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Crocchiolo
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: S
authors.initials: S
authors.lastname: Furst
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: El-Cheikh
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Granata
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: S
authors.initials: S
authors.lastname: Harbi
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Morabito
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
authors.forename: J
authors.initials: J
authors.lastname: Mariotti
authors.affiliation: Department of Hematology, Università degli Studi di Milano, Milano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Puvinathan
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: P J
authors.initials: PJ
authors.lastname: Weiller
authors.affiliation: Department of Hematology, Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France.|Department of Hematology, Aix-Marseille Université, Marseille, France.|Department of Hematology, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
authors.affiliation: Department of Hematology, Intensive Care Unit, Institut Paoli Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Mokart
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.|Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Carlo-Stella
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Department of Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.|Department of Hematology, Humanitas University, Humanitas Clinical and Research Hospital, Rozzano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Santoro
authors.affiliation: Department of Hematology, Transplantation Program, Marseille, France.|Department of Hematology, Aix-Marseille Université, Marseille, France.|Department of Hematology, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D016019:Survival Analysis; D000075442:Transplantation, Haploidentical / Q000379:methods* / Q000401:mortality; D055815:Young Adult
chemical_list: D003520:Cyclophosphamide